Table 1.
Summary of 3 cases in present series
| Variable | Case 1 | Case 2 | Case 3 |
|---|---|---|---|
| Age | 38 | 22 | 23 |
| Gender | Female | Male | Female |
| Location of tumor | Middle 3rd | Lower 3rd | Middle 3rd |
| Tumor differentiation | MDAC | PDAC/Signet | PDAC/Signet |
| Neoadjuvant treatment | SCRT f/b 4# CAPOX | 3# CAPOX f/b NACTRT f/b 4# CAPOX | SCRT f/b 4# CAPOX |
| PCI | 4 | 5 | 6 |
| Extent of surgery | Posterior exenteration + pelvic peritonectomy + omentectomy | Total pelvic exenteration + pelvic peritonectomy + omentectomy | Posterior exenteration + pelvic, paracolic peritonectomy |
| Blood loss (ml) | 500 | 750 | 600 |
| Duration of surgery (h) | 4 | 6 | 4 |
| CC score | 0 | 0 | 0 |
| HIPEC drugs | Adriamycin + Mitomycin | Oxaliplatin | Adriamycin + Mitomycin |
| Postoperative complications | Nil | Anastomotic dehiscence | Paralytic ileus |
| Clavien–Dindo grade (morbidity) | 0 | IIIb | II |
| Hospital stay | 7 | 12 | 10 |
| Pathological stage | pT4N0M1 | pT4N0M1 | pTxN0M1 |
| Last follow-up after surgery (months) | 24 | 12 | 30 |
| Recurrence | No | Yes | Yes |
MDAC moderately differentiated adenocarcinoma, PDAC poorly differentiated adenocarcinoma, SCRT short-course radiotherapy, NACTRT neoadjuvant chemoradiotherapy, CAPOX capecetabine + oxaliplatin-based chemotherapy, HIPEC hyperthermic intraperitoneal chemotherapy